{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:42:01Z","timestamp":1693734121228},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Severe recurrent proximal muscle weakness without neuroleptic malignant syndrome secondary to antidopaminergic medication has rarely been reported. We report a 29-year-old man with history of obsessive compulsive disorder and Tourette syndrome who presented with 2 months of worsening dyspnea 3 weeks after starting ziprasidone 40 mg daily that required mechanical ventilation. A year before, after an increased risperidone dose from 0.5 to 1 mg daily, he had developed proximal muscle weakness that spontaneously improved 2 months after discontinuation of risperidone. On this admission, his creatine kinase (CK) was 3318 units\/L, and ziprasidone was discontinued. He fully recovered 2 months after discontinuation of ziprasidone, and his CK was 62 units\/L. Genetic testing for limb\u2013girdle muscular dystrophy was negative. This case highlights the importance of evaluating CK level in patients taking antidopaminergic medication with any suggestion of muscle weakness to prevent potentially life-threatening complication.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000233","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T03:44:14Z","timestamp":1542339854000},"page":"94-98","source":"Crossref","is-referenced-by-count":3,"title":["Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome"],"prefix":"10.1097","volume":"20","author":[{"given":"Yohei","family":"Harada","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuhin","family":"Virmani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Gokden","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikki","family":"Stefans","sequence":"additional","affiliation":[{"name":"Pediatrics and"},{"name":"Physical Medicine and Rehabilitation, Arkansas Children's Hospital, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002130000464","article-title":"Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine","volume":"150","author":"Boot","year":"2000","journal-title":"Psychopharmacology (Berl)."},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0893-133X(95)00276-J","article-title":"Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment","volume":"15","author":"Meltzer","year":"1996","journal-title":"Neuropsychopharmacology."},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0960327106073832","article-title":"Olanzapine overdose is associated with acute muscle toxicity","volume":"25","author":"Waring","year":"2006","journal-title":"Hum Exp Toxicol."},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0897190013516509","article-title":"Antipsychotic use and the risk of rhabdomyolysis","volume":"27","author":"Packard","year":"2014","journal-title":"J Pharm Pract."},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.psychres.2005.05.003","article-title":"A rating scale for neuroleptic malignant syndrome","volume":"135","author":"Sachdev","year":"2005","journal-title":"Psychiatry Res."},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/WNL.47.6.1518","article-title":"Clozapine-induced myotoxicity in patients with chronic psychotic disorders","volume":"47","author":"Scelsa","year":"1996","journal-title":"Neurology."},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/cap.2014.0181","article-title":"Motor weakness related to risperidone","volume":"25","author":"Kilicaslan","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5935\/0103-507X.20150013","article-title":"Recurrent rhabdomyolysis secondary to hyponatremia in a patient with primary psychogenic polydipsia","volume":"27","author":"Aguiar","year":"2015","journal-title":"Rev Bras Ter Intensiva."},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/PEC.0000000000000405","article-title":"Recurrent rhabdomyolysis in a teenager with psychosis-intermittent hyponatremia-polydipsia syndrome","volume":"31","author":"Shenoi","year":"2015","journal-title":"Pediatr Emerg Care."},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.psym.2013.05.003","article-title":"A patient with multiple episodes of rhabdomyolysis induced by different neuroleptics","volume":"55","author":"Aggarwal","year":"2014","journal-title":"Psychosomatics."},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2174\/1389200217666160322143631","article-title":"The role of therapeutic drugs on acquired mitochondrial toxicity","volume":"17","author":"Moren","year":"2016","journal-title":"Curr Drug Metab."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201812000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:05:33Z","timestamp":1693631133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201812000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000233","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}